Target Name: ZIM2
NCBI ID: G23619
Review Report on ZIM2 Target / Biomarker Content of Review Report on ZIM2 Target / Biomarker
ZIM2
Other Name(s): ZIM2 variant 2 | Zinc finger, imprinted 2, transcript variant 2 | ZNF656 | Zinc finger imprinted 2 (isoform b) | Zinc finger protein 656 | Zinc finger imprinted 2 | Zinc finger imprinted 2, transcript variant 1 | zinc finger protein 656 | zinc finger imprinted 2 | ZIM2_HUMAN | ZIM2 variant 1

ZIM2: A Potential Drug Target Or Biomarker for Diabetes, Obesity and NASH

ZIM2 (Zinc Finger Nucleotide-conjugated Islet Helper Molecule 2) is a protein that is expressed in the pancreas, a gland that is responsible for producing insulin to regulate blood sugar levels. ZIM2 has been identified as a potential drug target or biomarker for several diseases, including type 1 diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

ZIM2 is a zinc finger nucleotide-conjugated protein that is composed of 115 amino acid residues. It is expressed in the pancreas and is involved in the production of insulin. Insulin is a hormone that helps regulate blood sugar levels. It is produced by the pancreas beta cells and is responsible for carrying out a critical function in maintaining the balance of glucose in the blood.

Recent studies have suggested that ZIM2 may have potential as a drug target or biomarker for several diseases, including type 1 diabetes, obesity, and NASH.

In type 1 diabetes, ZIM2 has been shown to be expressed in pancreatic beta cells and has been suggested as a potential drug target. Type 1 diabetes is a chronic autoimmune disease that is characterized by the destruction of insulin-producing beta cells in the pancreas. The destruction of beta cells leads to a lack of insulin production, which can result in high blood sugar levels. ZIM2 has been shown to be able to protect beta cells from immune-mediated destruction in animal models of type 1 diabetes.

In obesity, ZIM2 has been shown to be involved in the regulation of energy metabolism. Obesity is a condition that is characterized by excess body weight and can lead to a range of health problems, including cardiovascular disease, diabetes, and certain cancers. ZIM2 has been shown to be involved in the production of mitochondrial dysfunction, a condition that can occur in obesity. Mitochondrial dysfunction is characterized by the breakdown of mitochondrial DNA and can lead to the accumulation of toxic substances in the body.

In NASH, ZIM2 has been suggested as a potential biomarker for the disease. NASH is a type of non-alcoholic fatty liver disease (NAFLD) that is characterized by the accumulation of fat in the liver. ZIM2 has been shown to be involved in the production of fat in the liver, as well as in the regulation of insulin sensitivity. Insulin sensitivity is the ability of the body's cells to respond to insulin, a hormone that helps regulate blood sugar levels. The accumulation of fat in the liver, as well as the failure to respond to insulin, can lead to the development of NASH.

In conclusion, ZIM2 is a protein that has been identified as a potential drug target or biomarker for several diseases, including type 1 diabetes, obesity, and NASH. ZIM2 is involved in the production of insulin and has been shown to be involved in the regulation of beta cell function, energy metabolism, and insulin sensitivity. Further research is needed to fully understand the role of ZIM2 in these diseases and to determine its potential as a drug target or biomarker.

Protein Name: Zinc Finger Imprinted 2

Functions: May be involved in transcriptional regulation

The "ZIM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZIM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZIM3 | Zinc finger protein GLI | ZKSCAN1 | ZKSCAN2 | ZKSCAN3 | ZKSCAN4 | ZKSCAN5 | ZKSCAN7 | ZKSCAN8 | ZKSCAN8P1 | ZMAT1 | ZMAT2 | ZMAT3 | ZMAT4 | ZMAT5 | ZMIZ1 | ZMIZ1-AS1 | ZMIZ2 | ZMPSTE24 | ZMYM1 | ZMYM2 | ZMYM3 | ZMYM4 | ZMYM4-AS1 | ZMYM5 | ZMYM6 | ZMYND10 | ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207 | ZNF208 | ZNF209P | ZNF211 | ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221